ERBB2 and breast carcinoma: Based on the studies, T-DXd has been approved in not only HER2-positive breast cancer [11,12] but also HER2-mutant lung cancer [13] and HER2-low (IHC 1+ or IHC 2+/ISH-non-amplified) advanced breast cancer [14].